CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)
Publication
, Conference
Desjardins, A; Chandramohan, V; Landi, D; Peters, KB; Johnson, M; Khasraw, M; Low, J; Threatt, S; Bullock, C; Herndon, JEII; Lipp, ES ...
Published in: NEURO-ONCOLOGY
2022
Duke Scholars
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2022
Volume
24
Issue
7
Start / End Page
vii65 / vii65
Location
Tampa Convention Center, Tampa Bay, F L
Conference Name
2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Chandramohan, V., Landi, D., Peters, K. B., Johnson, M., Khasraw, M., … Bigner, D. (2022). CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS). In NEURO-ONCOLOGY (Vol. 24, pp. vii65–vii65). Tampa Convention Center, Tampa Bay, F L. https://doi.org/10.1093/neuonc/noac209.255
Desjardins, Annick, Vidya Chandramohan, Daniel Landi, Katherine B. Peters, Margaret Johnson, Mustafa Khasraw, Justin Low, et al. “CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS).” In NEURO-ONCOLOGY, 24:vii65–vii65, 2022. https://doi.org/10.1093/neuonc/noac209.255.
Desjardins A, Chandramohan V, Landi D, Peters KB, Johnson M, Khasraw M, et al. CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS). In: NEURO-ONCOLOGY. 2022. p. vii65–vii65.
Desjardins, Annick, et al. “CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS).” NEURO-ONCOLOGY, vol. 24, no. 7, 2022, pp. vii65–vii65. Manual, doi:10.1093/neuonc/noac209.255.
Desjardins A, Chandramohan V, Landi D, Peters KB, Johnson M, Khasraw M, Low J, Threatt S, Bullock C, Herndon JEII, Lipp ES, Sampson J, Friedman A, Friedman HS, Ashley D, Knorr D, Ravetch J, Bigner D. CTIM-23. DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS). NEURO-ONCOLOGY. 2022. p. vii65–vii65.
Published In
NEURO-ONCOLOGY
DOI
EISSN
1523-5866
ISSN
1522-8517
Publication Date
2022
Volume
24
Issue
7
Start / End Page
vii65 / vii65
Location
Tampa Convention Center, Tampa Bay, F L
Conference Name
2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences